A study published in the journal Issues in Law & Medicine has identified anti‑progesterone activity in water samples collected from three U.S. communities, including municipal tap water in Austin, Texas. Researchers used a PR‑CALUX biological assay that reports results as “mifepristone equivalents,” meaning the test shows activity similar to the abortion drug mifepristone but does not confirm the exact chemical present.
Key findings
Water was sampled upstream and downstream of wastewater‑treatment plants and directly from municipal taps in Austin, Blacksburg, Virginia, and Carbondale, Illinois. Anti‑progesterone activity appeared in eight of nine sampling categories, with the highest reading equivalent to roughly 41 parts per trillion of mifepristone. The authors stress that the assay does not prove the presence of mifepristone itself; other compounds could produce similar activity.
What the study does not show
The researchers caution that the data do not demonstrate that Americans nationwide are drinking mifepristone, nor do they establish a link between the trace amounts detected and infertility, miscarriage, or other health problems in humans. No epidemiological evidence currently connects environmental exposure to mifepristone with measurable reproductive outcomes.
Why the findings matter to Austin residents
Austin’s water utilities, like many across the country, treat wastewater before releasing it back into rivers and supplying drinking water. Conventional treatment does not always remove all pharmaceutical compounds. If further testing confirms the presence of mifepristone or related anti‑progesterone substances, the city may need to consider advanced treatment options such as activated carbon, ozonation, or membrane filtration.
Political response
In June 2025, Senator James Lankford (R‑OK) and Representative Josh Brecheen (R‑OK), along with more than 20 other Republican lawmakers, asked EPA Administrator Lee Zeldin to investigate whether mifepristone and its metabolites could be entering the nation’s water system. The request was reiterated in 2026 when 19 Republican members of Congress urged the EPA to consider adding mifepristone to its sixth Contaminant Candidate List, a step that could lead to future drinking‑water regulations under the Safe Drinking Water Act.
Next steps for testing and remediation
The study’s authors recommend larger, season‑spanning sampling efforts across diverse regions and the use of targeted analytical chemistry—such as liquid chromatography‑mass spectrometry—to determine whether mifepristone itself, its metabolites, or other anti‑progesterone chemicals are responsible for the observed activity. They also suggest measuring concentrations before and after treatment to assess removal efficiency.
For consumers, the FDA continues to advise using drug take‑back programs for unused medications and to avoid flushing drugs not listed on its flush‑list. While household disposal is one pathway for pharmaceuticals to enter wastewater, industrial discharge and excretion after medical use are additional routes.
Context of medication abortions
The study notes that the scale of medication abortions has grown. The Guttmacher Institute reported about 642,700 medication abortions in the U.S. health‑care system in 2023, representing 63 % of all abortions that year. Increased usage raises the potential for excreted drug residues to enter wastewater streams.
Environmental assessments from the 1990s acknowledged the possibility of pharmaceutical entry into water but concluded that adverse effects were unlikely at the concentrations then expected. The new data suggest that updated monitoring may be warranted.
What Austin can do now
City officials and the Austin Water utility can begin by commissioning independent laboratory analyses of tap water for mifepristone‑equivalent activity. If confirmed, the utility could evaluate advanced treatment technologies and coordinate with the Texas Commission on Environmental Quality to align with any forthcoming EPA guidance.
Community members concerned about water quality are encouraged to stay informed through public utility meetings, support drug‑take‑back events, and follow updates from the EPA’s pharmaceutical benchmark program, which currently tracks 374 FDA‑approved drugs that may appear in source or treated drinking water.
Original reporting: The Dallas Express — read the source article.
